Payment overview · 2025
General Payments
$1,079.24
35 reported records · 14 companies
Healthcare provider profile · identity verified
Keith Douglas Horner, MD
Allopathic & Osteopathic Physicians|Family Medicine · WACO, TX · NPI 1235103334
Verified facts
What the public records show
CMS Open Payments records show Keith Douglas Horner, MD received $1,079.24 in general payments during 2025 across 35 reported records.
Novo Nordisk Inc accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $285.48 | 26.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $174.85 | 16.2% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $135.94 | 12.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$116.53 | 10.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.67 | 7.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.51 | 6.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.34 | 4.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $41.37 | 3.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.67 | 2.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.43 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.45 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.33 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.06 | 1.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $11.61 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,079.24 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.52 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $135.94 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $118.59 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $116.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.34 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.82 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.67 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $11.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 416 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 80 |
| Lisinopril | Lisinopril | 290 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 80 |
| Losartan Potassium | Losartan Potassium | 285 | 63 |
| Gabapentin | Gabapentin | 214 | 46 |
| Montelukast Sodium | Montelukast Sodium | 193 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 41 |
| Telmisartan | Telmisartan | 156 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 29 |
| Sertraline Hcl | Sertraline Hcl | 146 | 35 |
| Metformin Hcl | Metformin Hcl | 125 | 29 |
| Azelastine Hcl | Azelastine Hcl | 122 | 45 |
| Alprazolam | Alprazolam | 114 | 28 |
| Tramadol Hcl | Tramadol Hcl | 108 | 27 |
| Omeprazole | Omeprazole | 104 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 27 |
| Metformin Hcl Er | Metformin Hcl | 102 | 25 |
| Simvastatin | Simvastatin | 102 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 24 |
| Carvedilol | Carvedilol | 95 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 20 |
| Trazodone Hcl | Trazodone Hcl | 94 | 22 |
| Eliquis | Apixaban | 83 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 17 |
| Clonazepam | Clonazepam | 72 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 18 |
| Allopurinol | Allopurinol | 67 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 66 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 17 |
| Glimepiride | Glimepiride | 65 | 20 |
| Ozempic | Semaglutide | 64 | 12 |
| Potassium Chloride | Potassium Chloride | 64 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 16 |
| Eszopiclone | Eszopiclone | 60 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 60 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 32 |
| Furosemide | Furosemide | 57 | 13 |
| Edarbi | Azilsartan Medoxomil | 56 | suppressed |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Cephalexin | Cephalexin | 53 | 45 |
| Mirtazapine | Mirtazapine | 52 | 15 |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 12 |
| Meloxicam | Meloxicam | 43 | 18 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Amoxicillin | Amoxicillin | 42 | 17 |
| Atenolol | Atenolol | 42 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Mupirocin | Mupirocin | 36 | 29 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Repaglinide | Repaglinide | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 11 |
| Fluconazole | Fluconazole | 24 | 12 |
| Finasteride | Finasteride | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 16 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Euthyrox | Levothyroxine Sodium | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Teriparatide | Teriparatide | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,079.24 · 35 records | Novo Nordisk Inc | ABRE, AIRSUPRA, AREXVY, Auvelity, BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error